2013年北京、成都、广州、上海四城市5-羟色胺3受体拮抗剂应用分析  

Use of 5-HT_3 Receptor Antagonists in Beijing,Chengdu,Guangzhou and Shanghai in 2013

作　　者：罗美娟[1] 曹媛[1] 王钰琦[1] 林颖[1] 

机构地区：[1]中山大学附属第一医院药学部,广东广州510080

出　　处：《中国医院用药评价与分析》2015年第6期772-774,共3页Evaluation and Analysis of Drug-use in Hospitals of China

摘　　要：目的:了解北京、成都、广州、上海四城市5-羟色胺3(5-HT3)受体拮抗剂的临床应用情况,为合理用药提供参考。方法:对《医院处方分析合作项目》组2013年北京、成都、广州、上海四城市5-HT3受体拮抗剂的处方数据进行分析,采用限定日剂量法计算用药频度、限定日费用。结果与结论:四城市5-HT3受体拮抗剂的销售金额和处方数均呈增长态势,使用品种均以昂丹司琼、托烷司琼为主,格拉司琼和帕洛诺司琼的使用在各地区间有较大差异。该类药物主要用于外科手术科室和肿瘤治疗相关科室。OBJECTIVE：To analyze the clinical use of 5-HT3 receptor antagonists in Beijing, Chengdu, Guangzhou and Shanghai in order to provide reference for clinical rational use of 5-HT3 .METHODS：The prescriptions of 5-HT3 receptor antagonists in the four cities in 2013 collected from “Project of Prescription Analysis Cooperation”were analyzed with regard to DDDs and daily drug cost （ DDC ） using defined daily dose method.RESULTS ＆CONCLUSIONS：The consumption sum and the number of prescriptions of 5-HT3 receptor antagonists in all four cities witnessed an increase.Ondansetron and tropisetron were predominantly used in the above-mentioned four cities.But the use of gramsetron and palonosetron varied greatly among different regions.5-HT3 receptor antagonists were mainly use in surgical department and cancer treatment department.

关 键 词：5-HT3受体拮抗剂 限定日剂量 处方数 销售金额 用药分析 

分 类 号：R975.4[医药卫生—药品]